Short-time QiBaoMeiRan Formula Treatment Exerts Estrogenic Activities without Side Effects on Reproductive Tissues in Immature Mice

Ying Xu1, Xiao-ping Ma1, Jin-na An1, Zi-jia Zhang2, Jin Ding1, Ya-kun Qu1, Zhen-li Liu3 & Na Lin1

The Chinese herbal preparation QiBaoMeiRan formula (QBMR) displayed estrogenic effects in ovariectomized rats after long-term administration in a previous study. The uterus and vagina are negatively influenced by estrogens in hormone therapy. While QBMR is known to be a phytoestrogen, its estrogenic effects and safety on reproductive tissues after short-term administration and its mechanism via estrogen receptor (ER) pathway haven’t been studied. Here, we characterized its estrogenic effects using immature mice together with in vitro studies for further molecular characterization. Immature mice were treated with QBMR at doses of 1.125, 2.25, and 4.5 g/kg for 7 days. 1.125 and 2.25 g/kg QBMR promoted the growth and development of uterus and vagina, and upregulated ERα and ERβ expression in reproductive tissues. QBMR had a stimulatory effect on proliferating cell nuclear antigen in vagina but not in uterus, and was without any influence on ki-67 antigen in uterus and vagina. QBMR significantly induced luciferase expression from the ERα/ERβ-estrogen response element (ERE) luciferase reporter and upregulated ERα and ERβ expressions in MCF-7 cells, which were significantly inhibited by estrogen antagonist ICI182,780. This study demonstrated QBMR exerts estrogenic effects on reproductive tissues without side effects and through ER-ERE-dependent pathway.

In climacteric and postmenopausal women, low serum levels of 17β-estradiol (E2) often result in hot flashes, sweating, anxiety, mood swings, as well as an increased risk for many chronic health problems, such as cardiovascular diseases and osteoporosis. These effects have prompted women to receive hormone replacement therapy (HRT) to prevent these aging-associated symptoms or diseases1,2. In the uterus, E2 stimulates endometrial proliferation without the addition of progestin; this stimulation results in endometrial hyperplasia and may possibly lead to neoplasia3. The vagina is another target for E2, since its epithelium is induced to undergo proliferation and cornification, which are the desired estrogenic effects because lactobacillus use these cells to produce lactic acid to keep the vaginal milieu...
Figure 1. The effects of QiBaoMeiRan formula (QBMR) on uterus. Data are the mean ± standard deviation (SD) of samples from 10 mice. P values are based on the results of a one-way analysis of variance (ANOVA) comparing the treatment group to untreated immature mice. **p < 0.001 **p < 0.01 and *p < 0.05, compared to the control group. *p < 0.05, compared with 1.125 g/kg group. (▲) p < 0.05, compared with ERα protein relative increase to Control. (A) The weights of uters were measured at the end of the 7-day treatment period. (B) The effects of QBMR treatment on the histology of the uterus in immature mice. Representative photomicrographs taken at 200× and 400× magnification. Insets (Fig. 1Bi-iv) show higher magnifications of endometrium (arrowhead). The square in (Fig. 1Bvi) indicates the area shown at higher magnification in (Fig. 1Bvi). (C) The effects of QBMR treatment on the expression of the estrogen receptor (ER) α, ERβ, proliferating cell nuclear antigen (PCNA) and ki-67 antigen in the uterus.
Representative photomicrographs taken at 200× magnification of ERα, ERβ, expression in the uterus, 100× magnification of PCNA and ki-67 expression in uterus sections from each treatment group are shown: (i) untreated immature mice, (ii) 1.125 g/kg, (iii) 2.25 g/kg, (iv) 4.5 g/kg QBMR, and (v) estradiol valerate (EV).

(D) The effects of QBMR on the protein expression levels of estrogen receptor (ER) α, ERβ, proliferating cell nuclear antigen (PCNA) and ki-67 in the uterus by western blot and the analyses were carried out as described in the Materials and Methods.

acidic and thus prevent ascending infections4. The uterus and vagina are known to be negatively influenced by estrogens used in HRT. Estrogens alone stimulate endometrial proliferation and may possibly lead to cancer5–7, which has led to a search for HRT alternatives, and plant-derived phytoestrogens have been vigorously promoted. Phytoestrogens are similar both structurally and functionally to mammalian estrogens, but with reportedly lower side effects than synthetic HRT8,9. Phytoestrogens can bind to estrogen receptors (ERs) and appear to have various estrogenic and antiestrogenic effects; therefore, they have been considered as selective estrogen receptor modulators (SERMs)10,11. Traditional Chinese medicines (TCM) containing multi-interactive compounds, which have been used for centuries in China to treat perimenopausal syndrome, have attracted the attention of researchers interested in using a TCM formula as a new phytoestrogen resource. QiBaoMeiRan formula (QBMR) recorded in the Chinese Pharmacopeia of 2010 and includes Polygoni Multiflori Radix, Angelicae Sinensis Radix, Achyranthis Bidentatae Radix, Semen Cuscutae, Fructus Lycii, Poria, and Fructus Psoraleae. In our previous study, QBMR exhibited estrogenic activity, as indicated by its interference with the atrophy of reproductive target tissues, such as the uterus, vagina, and mammary gland, in ovariectomized (OVX) rats. In addition, QBMR relieves the symptoms of hot flushes and body weight gain, which are induced by estrogen decline12. The Organization for Economic Co-operation recommends that tests for estrogenic activity be performed both in immature and ovariectomized (OVX) rats/mice13. Currently, little is known about the biological effects of QBMR in immature mice after short-term oral administration and whether QBMR, as has been reported for phytoestrogens, causes few side effects or whether they are endocrine disruptors that endanger the uterus or vagina. Furthermore, QBMR induces increased ER expression in reproductive target tissues, providing some molecular evidence for estrogenic activity12, however, the molecular characterization of the mechanism of action of QBMR via the estrogen receptor has not been characterized. In the present study, we describe the estrogenic effects of QBMR using an in vivo model of immature mice and in vitro assays in HEK 293 cells stably transfected with hER α/β-the estrogen response element (ERE) plasmid, and the ER antagonist ICI182, 780, as part of an ongoing effort to provide scientific data and further identify the mechanism of QBMR’s estrogenic effects.

Results

Uterus. *QBMR promoted the growth and development of the uterus.* To characterize the estrogenic effects of QBMR on reproductive targets, we treated immature mice with QBMR and compared the activity to a synthetic estrogen, estradiol valerate (EV). As expected, EV treatment induced a 2.4-fold increase in uterine weight compared to untreated immature mice (p < 0.001). QBMR (1.125 and 2.25 g/kg) significantly increased uterine weight (p < 0.05 or 0.01) and the dose of 2.25 g/kg resulted a maximum of 3.68-fold increase in uterine weight. Notably, the largest dose of QBMR did not decrease uterine weight compared to controls. Rather, it did not stimulate uterine weight (Fig. 1A).

Figure 1B shows microscopic preparations of representative uteri from one animal per treatment group. Histological analysis of uterus sections revealed that immature mice treated with EV or QBMR (1.125, 2.25 g/kg) substantially altered uterine morphology (Fig. 1Bii–v), as indicated by the thickening of the uterine endometrium, increased number of glands, and more extended glandular cavities compared with untreated controls. QBMR 4.5 g/kg decreased uterine cavity and the gland number compared to untreated mice. The morphological findings in the uteri of all animals were quantified and are presented in Table 1. In untreated controls, the endometrium was composed of single layered columnar epithelial cells, and no mitotic activity was detected in epithelial cells. Animals in the QBMR medium group (Fig. 1Biii–iii) endometrial cells were stimulated but no pathological signs were detected. The stromal cells of endometrial lamina propria were well organized and spindle shaped. Endometrial mitotic activity was found in 1 of 10 mice in the QBMR low dose treatment group, in 5 of 10 animals in QBMR higher group, and none in QBMR 4.5 g/kg group. EV (Fig. 1Bv) induced estrogenic features, causing the endometrial epithelium to become multilayered and hypertrophic and the glands hyperplastic in 8 of 10 animals. Mitotic activity was present in the endometrial cells in most animals at various degrees.

QBMR increased ERα subtype expression and exerted no effect on PCNA and Ki-67 in uterus. Figure 1C shows representative sections of the expressions of ERα, ERβ, PCNA, and Ki-67 in the uterus from each group and their corresponding quantitative analysis. The number of positive-expressing cells was counted and expressed as a percentage of the total number of cells. Treatment with either EV or QBMR 1.125 and 2.25 g/kg induced a clear up-regulation of ERα and ERβ, and the maximum increases were observed in the higher dose treatment groups (both p < 0.001). Meanwhile, ERβ upregulation was stronger than that of ERα (p < 0.05). ERs in the uterus were expressed in the epithelial cells of the endometrium, interstitial
cells, and smooth muscle cells in the QBMR-treated or EV-treated groups. EV significantly stimulated the expression of PCNA and Ki-67 (both $p < 0.01$), whereas QBMR, at the two doses exhibiting estrogenic activity, there was no significant change apparent in these parameters, either in the IHC or the bar graphs, and the highest dose caused a slight decrease in PCNA and Ki-67 expression. PCNA and Ki-67 in the uterus were expressed in the epithelial cells of the endometrium and glands in the QBMR- and EV-treated groups.

Further evidence for the interaction of QBMR with the ERα, PCNA, and Ki-67 were obtained by western blot. As shown in Fig. 1D, similar to the immunostaining results, a dose of 2.25 g/kg significantly upregulated the protein expression of ERα by 2.0-fold ($p < 0.001$) and ERβ by 2.6-fold, ($p < 0.001$) compared to a 2.8- and 3.3-fold upregulation of ERα and ERβ induced by EV versus untreated immature mice. In addition, ERβ upregulation by QBMR was more than that of ERα ($p < 0.05$). Meanwhile, EV significantly stimulated the expression of PCNA (p < 0.05) and Ki-67 (p < 0.05) by 20% and 30% increase, respectively, in the uterus compared to those of untreated immature mice, and QBMR had no significant effect on these parameters in the uterus.

**Vagina.** QBMR promoted vaginal cornification. The estrus cycle of all mice was monitored by daily inspection of vaginal epithelium cell smears. As shown in Fig. 2A, smears of the vaginal epithelium cells of the untreated immature mice consisted of leukocytes, indicating a diestrus. In contrast, the vaginal cells from the immature mice treated with QBMR at doses of 1.125, 2.25 g/kg or EV became keratinized after about 4 days of treatment, which indicates advanced estrus. Moreover, QBMR treatment prolonged the estrus status of the immature mice, suggesting very potent estrogenic activity. However, in 4.5 g/kg QBMR-treated mice, smears of the vaginal epithelium cells consisted of leukocytes that did not change during the treatment period.

QBMR promoted the growth and development of vaginal epithelium thickness. Figure 2B shows microscopic preparations of representative vagina from one animal per treatment group, the morphologic findings in vagina of all animals were quantified and are presented in Table 2. In untreated control and QBMR 1.125 g/kg group, only three to five cell layers were present, and no cornification was observed in 10 of 10 mice. Compared to untreated immature mice, the EV-treated animals (Fig. 2B v) displayed a typical squamous multilayered epithelium. Approximately 10–15 cell layers with cornification were observed in all 10 samples. In 1.125 g/kg QBMR-treated animals, epithelium thickness and the number of cell layers were augmented in some areas, and cornification was observed in 8 of 10 rats. An incipient cytoplasmatic vacuolization of epithelial cells was observed in 4 of 10 rats. Treatment with 2.25 g/kg QBMR (Fig. 2B ii) increased epithelial thickness and the number of cell layers (10 layers). Cornification was found in 9 of 10 animals, and no cytoplasmatic vacuolization was noted in all samples. Taken together, these studies provide evidence that QBMR has significant estrogenic potential in the vagina, which is weaker comparable to that of the synthetic estrogen EV.

**QBMR increased ER subtype and PCNA, and exerted no effect on Ki-67 expression in vagina.** Figure 2C shows that treatment with either EV or QBMR at 1.125 or 2.25 g/kg induced clear and comparable up-regulation of ERα and ERβ in the vagina (both $p < 0.001$). ERs in vagina were expressed in the vaginal epithelium cells of squamous and smooth muscle cells. EV significantly stimulated the expression of PCNA ($p < 0.001$) and Ki-67 ($p < 0.05$), 1.125 and 2.25 g/kg QBMR were effective in upregulating the expression of PCNA ($p < 0.01$), and exerted no effect on Ki-67 expression in the vagina, and QBMR 4.5 g/kg did not result significant changes in these parameters compared with untreated controls.

The western blot results in Fig. 2D clearly showed that compared to the control group, treatment with QBMR (2.25 g/kg) stimulated levels of ERα and ERβ 1.8- and 2.7-fold, respectively, in the vagina. Similarly, EV induced a 2.1- and 3.3-fold increase in ERα and ERβ in the vagina. Similar to the PCNA- and Ki-67-immunostaining results, EV significantly stimulated PCNA ($p < 0.001$) and Ki-67 ($p < 0.01$) expression by 50% and 40% increase in the vagina, respectively, compared to that of untreated immature mice, and the highest dose of QBMR (2.25 g/kg) had a significant effect on protein expression with a 25% increase in PCNA ($p < 0.01$), and exerted no influence on Ki-67 expression in the vagina.

| Group          | Spindle-shaped Lamina propria cells | Endometrial epithelium with mitosis | Hyperplastic/Hypertrophic glands |
|----------------|------------------------------------|------------------------------------|----------------------------------|
| Control        | 1/10                               | 0/10                               | 0/10                             |
| QBMR 1.125 g/kg | 6/10                               | 1/10                               | 0/10                             |
| QBMR 2.25 g/kg  | 9/10                               | 5/10                               | 1/10                             |
| QBMR 4.5 g/kg  | 2/10                               | 0/10                               | 0/10                             |
| EV 154 mg/kg    | 10/10                              | 10/10                              | 8/10                             |

Table 1. Summary of the physiological and pathological findings in the uteri of immature mice after treatment with E2 or QiBaoMeiRan formula (QBMR).
Figure 2. The effects of QiBaoMeiRan formula (QBMR) on vagina. Data are the mean ± standard deviation (SD) of samples from 10 mice. P values are based on the results of a one-way analysis of variance (ANOVA) comparing the treatment group with untreated immature mice. ***p < 0.001 **p < 0.01 and *p < 0.05, compared to the control group. #p < 0.05, compared to QBMR 1.125 g/kg group. (∆) p < 0.05, compared with ERα protein relative increase to Control. (A) The effects of QBMR on the estrus cycle.
Vaginal epithelial cell smears were taken at the seventh day from immature untreated mice (i), mice treated with QBMR 1.125 g/kg (ii), mice treated with QBMR 2.25 g/kg (iii), mice treated with QBMR 4.5 g/kg (iv), and mice treated with estradiol valerate (EV) (v). (B) The effects of QBMR treatment on vagina histology in immature mice. (C) The effects of QBMR treatment on the expression of ERα, ERβ, and PCNA in the vagina. Representative photomicrographs taken at 400× magnification of the uterus, ERα and ERβ expression in the vagina, 100× magnification of PCNA and ki-67 expression in the vagina sections from each treatment group are shown: (i) untreated immature mice, (ii) 1.125 g/kg, (iii) 2.25 g/kg, and (iv) 4.5 g/kg QBMR, and (v) EV. (D) The effects of QBMR formula on the protein expression levels of estrogen receptor (ER) α, ERβ, proliferating cell nuclear antigen (PCNA) and ki-67 in the vagina by western blot.

**QBMR increased E2 and decreased LH and FSH in serum.** Immature mice are expected to have lower levels of serum E2 and this is indicated in Fig. 3. Treatment of immature mice with QBMR at any doses or with EV raised levels of circulating E2 compared to those of untreated mice (p < 0.01). QBMR (2.25 g/kg) and EV treatment induced 2.2- and 2.7-fold increases in circulating E2, respectively (Fig. 3A). QBMR 1.125 and 2.25 g/kg significantly decreased the levels of serum LH and FSH, and at the higher dose exhibited significantly decreases in LH (37% reduction) and FSH (48% reduction) (Fig. 3B,C), which was a less effect comparable to the decrease induced by EV treatment.

**QBMR stimulated MCF-7 cell proliferation.** To investigate the particular basis of QBMR activity in more detail, we used MCF-7 human breast cancer cells as a model because they are dependent on estrogen for growth in monolayer culture. An ethanol extract of QBMR, QBMRE, was assessed for its effect on cell proliferation because QBMR powder is not soluble. Because the growth assays were not set up as one single experiment and plating densities varied, comparisons were made by expressing the results as the percentage number of doublings compared to the DMSO as control. Intermediate concentrations of QBMRE and 0.01 μM 17β-estradiol both stimulated proliferation (Fig. 4), demonstrating the estrogenic activity of the QBMR extracts, which were significantly inhibited by the specific ER antagonist ICI 182, 780.

**QBMR induced both ERα and ERβ transcriptional activity.** HEK 293 cells that had been stably transfected with the hERα/β-ERE-luciferase plasmid were used to measure the formation of functional hERα/β-ERE complexes in response to treatment with the QBMR extracts and/or individual compounds. Results are expressed as relative expression in DMSO-treated cells. QBMR increased both ERα and ERβ-ERE luciferase activity in a dose-dependent manner (Fig. 5A). QBMR extract at 0.1 mg/mL induced a 7.26-fold increase in ERα and a 23.4-fold increase in ERβ luciferase activity, which were comparable to the 7.3-fold increase in ERα and 27.5-fold increase in ERβ luciferase activity induced by 17β-estradiol at 0.01 μM. These effects were ablated when treatments were administered in the presence of the specific ER antagonist ICI182, 780, resulting in 84% and 96% inhibition of ERα and ERβ expression in cells treated with 0.1 mg/mL QBMR extract, respectively, which is comparable to that observed with 17β-estradiol treatment. These data indicate that QBMR clearly has estrogenic activity that is mediated through the activation of ERs. Moreover, Fig. 5B showed that QBMRE at any doses significantly increased ERα-ERE-luciferase activity induced by 17β-estradiol, whereas competitively activated ERβ-ERE luciferase expression along with 17β-estradiol. These results shown QBMRE had a dual action on ERα and ERβ but preferentially activated ERβ.

**QBMR upregulated ER subtype expression in MCF-7 cells.** Further evidence for the interaction of the QBMR extract with the ER system was sought by determining the effect of the extract on ER subtype expression in MCF-7 cells by western blotting. The results show that 0.1 mg/mL QBMRE upregulated ERα and ERβ expression by 1.96- and 2.2-fold, respectively. ERα and ERβ expressions were upregulated slightly less by QBMRE than by 17β-estradiol (Fig. 6). The effects of QBMR extract were significantly inhibited by the specific ER antagonist ICI182, 780, with a 47% decrease in ERα and a 29% decrease in ERβ, compared to a 63% decrease in ERα and a 30% decrease in ERβ induced by 17β-estradiol, suggesting that QBMRE mediates estrogenic activity via the ER pathway. Moreover, ERβ upregulation by QBMRE was stronger than that of ERα (p < 0.05).

**Discussion**

This study aimed to investigate the estrogenic effects and safety of QBMR on the uterus and vagina in immature mice after short-term administration, and molecular mechanism of its effect via the estrogen receptor pathway. The results show that QBMR promoted the growth and development of the uterus and vagina, upregulated ERα and ERβ expressions in reproductive target tissues, and had a stimulatory effect on PCNA in vagina but not in uterus, and without any effects on ki-67 antigen in reproductive tissues. QBMR was shown to exert its estrogenic activity via the ER-ERE-independent signal transduction pathway.

Previous studies have addressed the effects of QBMR on estrogen target tissues, hot flashes, and weight gain in OVX rats after a relatively long duration of application. Reports about effects after short-term...
administration, particularly concerning safety, are scarce. Hence, we observed the expression of PCNA and Ki-67 in the uterus and vagina of immature mice treated with QBMR. PCNA is a nuclear protein that is expressed in proliferating cells during the S phase of the cell cycle and is a useful tool in mammary, cervical, and endometrial cancer prognosis research\(^1^4,1^5\). Protein of proliferation intensity (Ki-67-antigen) is an excellent marker for determining the growth cell fraction of a given cell population\(^1^6\). The number of PCNA- and Ki-67-positive cells in the uterus and vagina significantly increased in the EV-treated group compared to the vehicle-treated group. PCNA and ki-67 analysis also indicates that QBMR has
Figure 5. Activity of QiBaoMeiRan formula extract (QBMRE) on estrogen receptor (ER) α/β - estrogen response element (ERE) luciferases reporter gene expression. (A) The effect of QBMRE on ER α/β - ERE luciferases reporter gene expression in HEK293 cells. (B) The effect of the combination of QBMRE and E2 on ER α/β - ERE luciferases reporter gene expression in HEK293 cells. Data are the mean ± standard deviation of quadruplicate analyses, expressed relative to that of treatment with 0.1% DMSO. *p < 0.05, **p < 0.01 compared to DMSO; ***p < 0.001 compared to 0.01 μM E2; (▲) p < 0.05, (▲▲) p < 0.01, (▲▲▲) p < 0.001, (▲▲▲▲) p < 0.001, (▲▲▲▲▲) p < 0.01, (▲▲) p < 0.05, compared with ERα-ERE luciferases reporter gene expression relative increase to Control.

Figure 6. Estrogen receptor α (ER α) and ERβ expression in MCF-7 cells. Western blot analysis of ER subtype expression in MCF-7 cells was carried out as described in the Materials and Methods. *p < 0.05, compared to DMSO; **p < 0.05, ***p < 0.001, compared to 0.01 μM E2; (▲) p < 0.05, compared to QBMRE. (▲▲) p < 0.05, compared with ERα protein relative increase to Control.

a clear stimulatory effect on the vagina but not on the uterus compared to the control untreated group. The data reveal that estrogenic responses induced by QBMR show tissue variation that may reflect different affinities of PCNA and Ki-67 for QBMR components. Stimulated uterus cell proliferation is a risk
factor for the development of cancer17, and the PCNA and ki-67 cell proliferation marker results suggest that QBMR treatment for a short time is maybe safer in the uterus than EV treatment. Moreover, ERα is required for the development of cervical and vaginal cancers, long-term use of drugs that consist of more components acting as ERα-selective agonists could increase the risk of carcinogenesis19. It has been reported that ERα and ERβ produce opposite effects on human breast cancer cell proliferation and tumor formation20. ERα mediates the breast cancer-promoting effects of estrogens, and ERβ mediates its inhibitory effects. The ERα:ERβ ratio changes during the process of tumorigenesis with an increase in ERαs and a decrease in ERβ expression. This phenomenon has been observed in relation to breast20, colon21, and prostate22 cancers. We found that QBMR upregulated ERβ expression more significantly than ERα in the uterus (Fig. 1C,D) and vagina of immature mice (Fig. 2C,D), and the same effects on ERs subtype were also found in OVX rats after a long QBMR treatment12. These results suggesting that QBMR could induce agonistic or antagonistic effects depending on target organs, such as ERα and ERβ, and QBMR was safe for reproductive target tissue, maybe owing to a balanced ratio of ERα:ERβ. Mammary gland is one target for estrogen; however, compared to our previous study, we did not observe the effect on mammary gland because of the limited sample number of immature mouse models available.

Doses of QBMR were calculated based on guidelines published by the Center for Drug Evaluation and Research of the U.S. Department of Health and Human Sciences, in which estimates are given for equivalent doses in humans and common laboratory animals. The highest dose selected in the present study was based on a recommended dose of 0.45 g/kg in humans, as the dose dependency of some responses suggests that the range of doses could have been extended to lower doses. Of the three doses of QBMR used, the middle dose, 2.25 g/kg, induced the most profound physiological responses in immature mice. The highest dose of QBMR 4.5 g/kg, only increased serum estradiol and decreased LH and FSH levels, albeit to a lesser extent than the lower dose. These responses were not accompanied by promotions in the development of uterus and vagina tissue and ERs upregulation of ERs in target tissue. The weaker responses elicited at the highest doses suggest that these doses are on the downward slope of a bell-shaped, or biphasic, dose-response relationship consistent with some phytoestrogens23, which also suggest QBMR maybe is safe for reproductive tissues of immature mice in a short treatment because without increasing response accompany with increasing dose. Interestingly, in our previous OVX rat research, the lowest dose of QBMR induced the most profound physiological response in decreasing hot flashes12. The data suggest that estrogen response induced by QBMR show tissue variation that may reflect different affinities of ERs for QBMR components.

Estrogens are mainly synthesized in the ovary. The increased serum estrogen concentration after treatment with QBMR suggests that the effect of QBMR may be mediated through the hypothalamus-pituitary-ovary axis and stimulate the biosynthesis of estrogen in the ovary. Meanwhile, QBMR could increase the serum estradiol level in OVX rats in our previous study12. It is worth mentioning that the stimulation of estrogen synthesis in premature ovarian failure animals when they were administrated by other phytoestrogens24. Moreover, the increase in serum estradiol levels cause a decrease in FSH and LH production, inhibiting or negative feedback of GnRH production in the hypothalamus25–26. Our results suggested QBMR induced higher estrogen release and inhibited the secretion of FSH and LH maybe by negative feedback regulation.

Estrogen mediates its actions by binding to the ER and inducing a major conformational change, causing the estrogen-ER complex to relocate to the nucleus to bind to its cognate DNA response element (ERE) located in the promoter/enhancer regions of target genes, allowing the regulation of gene transcription27,28. Under physiological conditions, the biological effects of estrogen depend not only on estrogen levels, but also on the distribution and expression levels of the corresponding ERs in the target cell, ERα and ERβ. The MCF-7 cell line expresses ERs and is dependent on estrogen for proliferation in monolayer culture29–33. Using an ethanol extract of the complete QBMR formula, we found that QBMRE at the two intermediate doses induced moderate proliferation of MCF-7 cell. At the same concentrations, QBMRE could significantly stimulate the activity of an ERα/β-ERE-luciferase reporter gene in HEK 293 cells. QBMR was more effective at stimulating the ERβ-ERE luciferase reporter than ERα-ERE luciferase reporter. Both QBMRE and agonist activity were strongly inhibited by the ER antagonist ICI182, 780, which suggests that QBMR exhibited estrogenic activities via the ERE pathway by interacting with the estrogen receptor. Similar effects were found on the expression levels of ERs in MCF-7 cells, in which QBMRE induced an upregulation of ERα and ERβ, similar in magnitude to the estrogen agonist 17β-estradiol, and all responses were inhibited by ICI182, 780. ERβ upregulation induced by QBMRE in MCF-7 cell was stronger than that of ERα (Fig. 6), which also corresponds with ERs transcriptional activity detection in HEK 293 cells with stably transfected the hERα/β-ERE-luciferase plasmid (Fig. 5).

Based on the increases of ERβ expression by QBMR than that of ERβ in the uterus (Fig. 1C,D) and vagina of immature mice (Fig. 2C,D), suggesting that QBMR maybe bind to ERβ with higher selectivity than ERα. Other phytoestrogens have also been reported to have a higher affinity and selectivity for ERβ28. Long-term use of those drugs that consist of more components acting as ERα-selective agonists could increase the risk of carcinogenesis30, which may explain why phytoestrogen is safer than HRT.

This study provides evidence that QBMR acts as an estrogen agonist. Further studies are in progress in our laboratory to investigate the use of QBMR as an effective dietary supplement to improve the quality of life for menopausal women and to identify the estrogenic compounds in the QBMR.
Materials and Methods

In vivo studies. Animals and experimental design. The experimental protocol was approved by the Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences and all methods were carried out in accordance with the approved guidelines.

Female, 21-day-old, immature mice (12 ± 2 g) were purchased from Experimental Animal Center of the Academy of Military Medical Sciences (Certificate No. SCXK [Jun] 2012-0004). The immature mice were randomly assigned to five groups: control group (Con, n = 10), immature mice were orally administrated with 0.154 mg/kg estradiol valerate or intragastrically at a daily dose of 1.125, 2.25, or 4.5 g/kg (QBMR, n = 10 in per group) for 7 days. Dose calculations followed guidelines correlating the dose equivalents between humans and laboratory animals based on ratios of body surface area. Untreated control mice received distilled water only.

Herbal preparation. QBMR was prepared as described in the Chinese Pharmacopeia of 2010. Briefly, the seven ingredients, including Polygoni Multiflori Radix (128 g), Angelicae Sinensis Radix (32 g), Achyranthis Bidentatae Radix (32 g), Semen Cuscutae (32 g), Fructus Lycii (32 g), Poria (32 g), and Fructus Psoraleae (16 g), were pulverized to a fine powder, suspended in distilled water to a concentration of 0.45 g/mL, and the contents of the representative chemical compositions were described in our previous report12. The sample for cell culture assays was prepared by extracting the powder with eight-fold volume of 70% ethanol (three times, for 1 h each). The combined extracts (QBMRE) were concentrated in vacuo and dissolved in DMSO (1 g/mL). The contents of representative chemical compositions in QBMRE for cell culture were determined by HPLC. The data were obtained using an Agilent 1200 Series HPLC with DAD. A Zobax SB-C18 column (4.6 mm × 250 mm; 5 μm; Agilent Technologies, Santa Clara, CA, USA) was used. The mobile phase consisted of 0.1% formic acid (A) and methanol (B) with a gradient elution flow rate of 1.0 mL/min. The gradient program (A/B, v/v) was as follows: 93:7 (t = 0 min), 42:58 (t = 18 min), 35:65 (t = 18.5 min), 35:65 (t = 30 min), 0:100 (t = 30 min), and 0:100 (t = 50 min). The detection wavelength program was 320 nm (t = 0 ~ 17 min), 316 nm (t = 17.01 ~ 18.30 min), 254 nm (t = 18.31 ~ 21.00 min), 246 nm (t = 21.01 ~ 28 min), and 254 nm (t = 28.01 ~ 40 min). The column temperature was set to 40°C. The HPLC chromatogram is shown in Fig. 7. The contents of 2,3,5,4′-stilbeneglucoside (0.054%), ferulic acid (0.00036%), β-ecdysone (0.00044%), psoralen (0.0021%), quercetin (0.0021%), isopsoralen (0.0012%), emodin (0.0027%), and physcion (0.0017%) in QBMR ethanol extracts were determined.

Analysis of vaginal cornification, target tissue, and serum sex hormones. Vaginal epithelium cell smears were performed for every mouse during the 7-day administration period12, and keratinized vaginal cells visualized by microscopy were considered indicative of estrus. All mice were sacrificed by decapitation after 7 days of treatment. Blood was collected from the eyeball and 50 μL serum for analysis of estradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) levels by enzymelinked immunosorbent assay (ELISA) (Beijing Xinfangcheng Biotechnology, China)39. The sensitivities of the three ELISA assays were 1.0 pg/ml, 1.0 mIU/ml and 1.0 ng/ml respectively and not soluble structural analogues with other cross-reaction, and all the intra-assay and inter-assay variation of each hormonal assay were less than 9% and 15%.
The uterus and vagina were removed and weighed. The left horns of the uterus and the upper portion of the vagina were stored at −80°C for analysis by western blot. The right horns of the uterus and the under portion of vagina were fixed with 4% polyoxymethylene for 24h. All samples were embedded in paraffin and prepared for cross sections; sections 4-μm thick were cut, mounted, and stained with Hematoxylin & Eosin (HE) for microscopy (Olympus, Tokyo, Japan).

Immunohistochemistry. The immunohistochemistry protocol and semi-quantitative analysis were carried out as described in our previous study. The following antibodies were used: rabbit anti-estrogen receptor-α polyclonal antibody (1:20, SC-542, Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit anti-estrogen receptor-β polyclonal antibody (1:50, Ab3577, Abcam Biotechnology, Cambridge UK), rabbit anti-estrogen receptor-β polyclonal antibody (1:200, SC-542, Santa Cruz Biotechnology), and rabbit anti-estrogen receptor-β polyclonal antibody (1:200, SC-7907, Santa Cruz Biotechnology) were used. The Image-Pro Plus 6.0 System image analysis system was used for quantitative analysis.

Western blot. The western blot protocol and semi quantitative analysis were carried out following the protocol of our previous study. The following antibodies were used: rabbit anti-estrogen receptor-α polyclonal antibody (1:200, SC-542, Santa Cruz Biotechnology), rabbit anti-estrogen receptor-β polyclonal antibody (1:1000, Ab3577, Abcam Biotechnology), rabbit anti-PCNA polyclonal antibody (1:200, SC-7907, Santa Cruz Biotechnology), and rabbit anti-glyceraldehyde 3-phosphate dehydrogenase (GAPDH) monoclonal antibody (1:1000, SC-7907, Cell Signaling Technology, Danvers, MA, USA). The relative quantity of each antibody was measured by AlphaEase FC (Fluorchem FC3) software. The density ratio of protein to GAPDH was calculated from the band density.

In vitro studies. MTT assay of MCF-7 cell proliferation. The MCF-7 cell line was purchased from Xiehe Cell Research Institute of Peking Union Medical College. They were maintained in Dulbecco’s modified eagle’s medium (DMEM) and 10% heat-inactivated fetal bovine serum (FBS; v/v). To minimize the effects of endogenous estrogens, cells were primed for at least 2 days in Phenol Red-free medium containing 5% charcol-stripped FBS, and then seeded (2 × 10^4 cells/180 μL/well) in 96-well plates. Cells were preincubated overnight in estrogen-depleted medium and test samples of QBMR extract (20 μL/well) at varying concentrations in DMEM, 17β-estradiol, the test samples with ICI182, 780 and 0.1% DMSO solvent blank (the same final concentration of DMSO in QBMR and 17β-estradiol solutions) were added. The test samples were incubated at 37°C for 2 days. Proliferation was determined by the MTT 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium (MTT) assay and 17β-estradiol (0.01 μM). MCF-7 cells were depleted of E2, as described above, preincubated overnight in estrogen-depleted medium and then seeded (1 × 10^5 cells/100 μL/well) in 96-well plates. The test samples with or without ICI182, 780 and 17β-estradiol were added to three replicate wells, as described for the MTT assay of MCF-7 cell proliferation, and was incubated for 24 h. Finally, the growth medium was carefully removed and 50 μL of MTT buffer per well was added, and the plate was rocked for 15 min. Twenty microliters of the detached cells solution was then transferred to a white micro well plate. Luciferase assay reagent (50 μL) was added to each well, and luciferase activity was measured immediately. Activity of the luciferase reporter gene was expressed relative to the DMSO control samples. Results reported are the mean ± standard deviation of three replicate determinations from a representative assay.

Transfection and reporter assay of estrogen receptor subtype selectivity. HEK 293 cells were stably transfected with human estrogen receptor α/β (hER α/β) and the estrogen response element (ERE) plasmid (kindly provided by Professor Yung-Chi Cheng, Yale University), and the luciferase reporter assay system from Promega (WI, USA) was used to evaluate the formation of functional ERα/β-ERE complexes. The cells were maintained and primed to minimize the effects of endogenous estrogens as described above and then seeded (1 × 10^5 cells/100 μL/well) in 96-well plates. The test samples with or without ICI182, 780 and 17β-estradiol were added to three replicate wells, as described for the MTT assay of MCF-7 cell proliferation, and was incubated for 24 h. Finally, the growth medium was carefully removed and 50 μL of MTT buffer per well was added, and the plate was rocked for 15 min. Twenty microliters of the detached cells solution was then transferred to a white micro well plate. Luciferase assay reagent (50 μL) was added to each well, and luciferase activity was measured immediately. Activity of the luciferase reporter gene was expressed relative to the DMSO control samples. Results reported are the mean ± standard deviation of three replicate determinations from a representative assay.

Measurement of ERO and ERβ expression. MCF-7 cells were depleted of E2, as described above, preincubated overnight in estrogen-depleted medium at a density of 1 × 10^5 cells per dish, and then treated with QBMR (0.1 mg/mL) or 17β-estradiol (0.01 μM) with or without 0.1 μM ICI182, 780 and 0.1% DMSO treatment as negative control. All cells were incubated for 48 h and were harvested protein. The western blot protocol and semiquantitative analysis were carried out using the following protocol: ERα antibody (1:200, SC-542 Santa Cruz Biotechnology) and ERβ antibody (1:1000, Ab3577, Abcam Biotechnology) were used, and GAPDH antibody (1:1000, SC-7907, Cell Signaling Technology) was used as internal control. All experiments were performed in triplicate. Mean normalized protein expression ± S.E. was calculated from independent experiments.

Statistics Analysis
The SPSS software version 11.0 for Windows (SPSS Inc, Chicago, IL, USA) was used for statistical analysis. All data were expressed as mean ± standard deviation and were analyzed by one-way analysis of
variance (ANOVA) followed by least significant difference (LSD) or Dunnett's T3 test. Differences were considered statistically significant when p was less than 0.05.

References
1. Burger, H. Hormone replacement therapy in the post-Women's Health Initiative era. Report a meeting held in Funchal, Madeira, February 24-25, Climacteric: the journal of the International Menopause Society 6, 11–36 (2003).
2. Grady, D. Postmenopausal hormones-therapy for symptoms only. N Engl J Med. 348,1839–1854 (2003).
3. Albertazzi, P. & Sharma, S. Urogenital effects of selective estrogen receptor modulators: a systematic review. Climacteric. 8, 214–220(2005).
4. Hertrampf, T. E. Effects of genistein on the mammary gland proliferation of adult ovariectomised Wistar rats. Planta Med. 72(4): 304–310(2006).
5. Xin, D. et al. Phytoestrogens from Psoralea corylifolia reveal estrogen receptor-subtype selectivity. Phytoecdinc. 17, 126–131(2010).
6. Fernandez, E. et al. Hormone replacement therapy and cancer risk: a systematic analysis from a network of case-control studies. Int J Cancer. 105, 408–412. (2003).
7. Humphries, KH. & Gill, S. Risks and benefits of hormone replacement therapy: The evidence spreds. Can Med Assoc J. 168, 1001–1010. (2003).
8. Beck, V., Rohr, U. & Jungbauer, A. Phytoestrogens derived from red clover: an alternative to estrogen replacement therapy? J. Steroid. Biochem. 94, 499–518(2005).
9. Benassayag, C., Perrot-Applanat, M. & Ferre, P. Phytoestrogens as modulators of steroid action in target cells. J. Chromatogr. B, 777, 233–248(2002).
10. Albertazzi, P. & Purdie, D. W. The nature and utility of the phytoestrogens: a review of the evidence. Maturitas. 42, 173–185(2002).
11. Poluzzi, E. et al. Phytoestrogens in postmenopausal: the state of the art from a chemical, pharmacological and regulatory perspective. Current medicinal chemistry. 21, 417–436 (2014).
12. Xue, Y. et al. Treatment with QiBaoMeiRan: A Kidney-Invigorating Chinese Herbal formula, Antagonizes the Estrogen Decline in Ovariectomized Rats. Rejuven. Res. 17, 372–381(2014).
13. Kann, J. et al. The OECD program to validate the rat uterotrophic assay: to screen compounds for in vivo estrogenic responses: Phase 1. Environ. Health. Persp. 109, 785(2001).
14. Kurki, P., Vanderlaan, M., Dolbeare, F., Gray, J. & Tan, E. M. Expression of proliferating cell nuclear antigen (PCNA)/cyclin during the cell cycle. Exp. Cell. Res. 166, 209–219(1986).
15. Schimmelpennung, H., Eriksson, E. T., Fanzen, B., Zetterberg, P.-Å. & Aner, G. U. Prognostic value of the combined assessment of proliferating cell nuclear antigen immunostaining and nuclear β-ENa content in invasive human mammary carcinomas. Virchows. Arch. 423, 273–279(1993).
16. Mambedli, L. et al. Changes in expression pattern of selected endometrial proteins following menopause induced stem cells infusion in mares with endometrosis. PLoS One. 9, e97989(2014).
17. Gadducci, A., Biglia, N., Sismondi, P. & Scriminazzan, A. R. Breast cancer and sex steroids: critical review of epidemiological, experimental and clinical investigations on estoprogenesis, chemoprevention and endocrine treatment of breast cancer. Gynecol. Endocrinol. 20, 343–360(2005).
18. Chung, S. H. & Lambert, P. R. Phytoestrogens and treatment of cervical cancer in mice using estrogen receptor antagonists. P. Natl. Acad. Sci. USA. 106, 19467–19472(2009).
19. Paruthiyil, S. et al. Estrogen receptor-beta inhibits human breast cancer cell proliferation and tumor formation by causing a G2 cell cycle arrest. Cancer Res. 64, 423–428(2004).
20. Shaaban, A. M. et al. Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am. J. Surg. Pathol. 27, 1502–1512 (2003).
21. Campbell-Thompson, M., Lynch, J. J. & Bhardwaj, B. Expression of estrogen receptor (ER) subtypes and ER beta isoforms in breast cancer. Cancer Res. 61, 632–640 (2001).
22. Fixemer, T., Kalsner, E. & Ponkonhoff, H. Differential expression of the estrogen receptor beta (ER beta) in human prostate tissue: nongenomic changes, and in primary, metastatic, and recurrent prostate adenocarcinoma. Prostate. 54, 79–87 (2003).
23. Xu, Y. et al. Treatment with Qing’E, a kidney-invigorating Chinese herbal formula, antagonizes the estrogen decline in ovariotrophically ovariectomized mice. Rejuvenation Res. 13, 479–488(2010).
24. Liu, L. et al. American ginseng regulates gene expression to protect against premature ovarian failure in rats. Biomed Res Int. 2014, 101155/ bami 767124 (2015).
25. Chen, J., Soma, K.K. & Sinchak, K. Neuropeptidergic: Key to estrogen positive feedback? Brain Res Rev. 57, 470–480 (2008).
26. Mahesh, V. B. Hirsutism, virilism, polycystic ovarian disease, and the steroid-gonadotropin-feedback system: A career retrospective. Am J Physiol Endocrinol Metab. 302, E4–E18 (2012).
27. Shao, W., Keeton, E. K., McDonnell, D. P. & Brown, M. Coactivator AIB1 links estrogen receptor transcriptional activity and stability. P. Natl. Acad. Sci. USA. 101, 11599–11604 (2004).
28. Hou, J., Liang, X.Y. & MiLM. Effects of y9902 on the proliferation and differentiation of MC3T-EL cells. Chin. Pharmacol. Bull. 22, 529–532(2006).
29. Green, S. & Chambron, P. Carcinogenesis: a superfamily of potentially oncogenic hormone receptors. Nature. 324, 615–617(1986).
30. Kupper, S., Nenmark, E., Pelo-Huikkko, M., Nilsson, S. & Gustafsson, J. A. Cloning of a novel receptor expressed in rat prostate and ovary. P. Natl. Acad. Sci. USA. 93, 5925–5930(1996).
31. Moselmann, S., Polman, J. & Dijkema, R. ERβ: Identification and characterization of a novel human estrogen receptor. Febbs. Lett. 392, 49–53 (1996).
32. Pelletier, G., Labrie, C. & Labrie, F. Localization of oestrogen receptor alpha, oestrogen receptor beta and androgen receptors in the rat reproductive organs. J. Clin. Endocr. Metab. 165, 359–370 (2000).
33. Saunders, P., Maguire, S., Gaughan, J. & Millar, M. Expression of oestrogen receptor beta (ER beta) in multiple rat tissues visualised by immunohistochemistry. J. Clin. Endocr. Metab. 154, R13–R16(1997).
34. Shughrue, P.I., Lane, M.V., Scrimo, P.I. & Merchenthaler.I. Comparative distribution of estrogen receptor-α (ER-α) and (and ER-β) mRNA in the rat pituitary, gonad, and reproductive tract. Steroids. 63, 498–504 (1998).
35. Darbre, P.D. & Daly, R.J. Effects of oestrogen on human breast cancer cells in culture. Prog. Soc. Edinb. A. 95B, 119–132(1989).
36. Byford, J. R. et al. Oestrogen activity of parabens in MCF7 human breast cancer cells. J. Steroid. Biochem. Mol. Biol. 80, 49–60(2002).
37. Matsumura, A., Ghosh, A., Pope, G.S. & Darbre, P.D. Comparative study of oestrogenic properties of eight phytoestrogens in MCF7 human breast cancer cells. J. Steroid. Biochem. Mol. Biol. 94, 431–443 (2005).
38. Sotoca, A. M. et al. Phytoestrogennemediated inhibition of proliferation of the human T47D breast cancer cells depends on the ER[alpha]/ER[beta] ratio. J. Steroid Biochem. Mol. Biol. 112, 171–178(2008).
39. Xu, Y. et al. Treatment with Panax Ginseng Antagonizes the Estrogen Decline in Ovariectomized Mice. *Int J Mol Sci* **15**, 7827–7840 (2014).
40. Xue L. et al. Comparative effects of er-xian decoction, epimedium herbs, and icariin with estrogen on bone and reproductive tissue in ovariectomized rats. *Evid-based Compl Alt*. 241416; doi: 10.1155/ecam/241416 (2012).

**Acknowledgements**
This work was supported by the grants from project of National Natural Science Foundation of China (81102826, 81573632) and the Fundamental Research Funds for the Central public welfare research institutes (ZZ070826).

**Author Contributions**
X.Y. and L.N. conceived and designed the experiments and supervised study and wrote the manuscript. M.X., A.J., D.J., Z.Z. and Q.Y. performed most of the experiments and statistical analysis. L.Z. carried out the HPLC analysis. All authors reviewed the manuscript.

**Additional Information**
Competing financial interests: The authors declare no competing financial interests.

*How to cite this article:* Xu, Y. et al. Short-time QiBaoMeiRan Formula Treatment Exerts Estrogenic Activities without Side Effects on Reproductive Tissues in Immature Mice. *Sci. Rep.* **5**, 17436; doi: 10.1038/srep17436 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/